Analysis Tools
integument
|
• mice administered doxycycline at weaning develop spontaneous melanoma after an average of 15 weeks with a 50% penetrance
• withdrawal of doxycycline results in rapid, durable and complete tumor regression within 10 days
• doxycycline treated mice administered the MEK inhibitor Selumetinib or GSK1120212 show tumor stasis but not tumor regression
• doxycycline treated mice administered a selective inhibitor of CDK4/6, PD-0332991 together with either Selumetinib or GSK1120212 show tumor regression
|
neoplasm
|
• mice administered doxycycline at weaning develop spontaneous melanoma after an average of 15 weeks with a 50% penetrance
• withdrawal of doxycycline results in rapid, durable and complete tumor regression within 10 days
• doxycycline treated mice administered the MEK inhibitor Selumetinib or GSK1120212 show tumor stasis but not tumor regression
• doxycycline treated mice administered a selective inhibitor of CDK4/6, PD-0332991 together with either Selumetinib or GSK1120212 show tumor regression
|
